Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
  • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/32—One oxygen, sulfur or nitrogen atom
  • C07D239/42—One nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
  • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Definitions

• This invention relates to cyclohexane derivatives, to processes for their preparation, 5 to pharmaceutical compositions containing such compounds and to their use in medicine.
• Gp Ilb/ma is the fibrinogen binding site on platelets that mediates the adhesive function required for platelet aggregation and thrombus formation.
• the invention thus provides the compounds of formula (I)
• X 1 , X 2 and Y 1 which may be the same or different, represent CH or N;
• Y 2 represents N or, when Y 1 represents N, may also represent CH;
• R 1 represents a hydrogen atom or a hydroxyl, C M alkyl or 2,2,2- trifluoroethyl 0 group
• R 2 represents a hydrogen atom or, when both X 1 and X 2 represent CH, may also represents a fluorine, chlorine or bromine atom or a phenyl or C M alkyl group;
• R 3 represents a hydrogen atom or, when both Y 1 and Y 2 represent N, may also represents a C M alkyl or hydroxymethyl group. 5
• ring -A- and ring -B- will hereinafter be used to described certain rings of formula (I):
• salts referred to above will be the physiologically acceptable salts, but other salts may find use, for example in the preparation of compounds of formula (T) and the physiologically acceptable salts thereof.
• Suitable physiologically acceptable salts of the compounds of formula (T) include acid addition salts formed with inorganic or organic acids (for example hydrochlorides, hydrobromides, sulphates, phosphates, benzoates, naphthoates, hydroxynaphthoates, p> toluenesulphonates, methanesulphonates, sulphamates, ascorbates, tartrates, salicylates, sucdnates, lactates, glutarates, glutaconates, acetates, tricarballylates, citrates, fumarates and maleates) and inorganic base salts such as alkali metal salts (for example sodium salts).
• inorganic or organic acids for example hydrochlorides, hydrobromides, sulphates, phosphates, benzoates, naphthoates, hydroxynaphthoates, p> toluenesulphonates, methanesulphonates, sulphamates,
• salts of the compounds of formula ( ) include salts formed with trifluoroacetic acid.
• the present invention encompasses all isomers of the compounds of formula (L) and their salts and solvates, including all tautomeric and optical forms, and mixtures thereof (e.g. racemic mixtures).
• alkyl 1 as a group or part of a group means a straight or branched chain alkyl group, for example a methyl, ethyl, n- propyl, i-propyl, n-butyl, s-butyl or t-butyl group.
• a preferred group of compounds of the invention are those of formula (la)
• a particularly preferred compound of the invention is cis-4-[4- [4-(ammoiminomethyl)phenyl]-l-piperazinyl]-l- hydroxycyclohexaneacetic acid and physiologically acceptable salts and solvates thereof.
• the compounds of the present invention are of interest for use in human and veterinary medicine, particularly in the treatment or prophylaxis of thrombotic disorders.
• thrombotic disorders include occlusive vascular diseases such as myocardial infarction, cardiac fatalities, angina, transient ischaemic attacks and thrombotic stroke, arteriosclerosis, vessel wall disease, peripheral vascular disease, nephropathy, retinopathy, postoperative thrombosis, pulmonary embolism, deep vein thrombosis and retinal vein thrombosis.
• the compounds of the invention are also of interest for use in the prophylaxis of peri- and postoperative complications following organ transplantation (particularly cardiac and renal), coronary artery bypass, peripheral artery bypass, angioplasty, thrombolysis and endarterectomy.
• the compounds of the invention may also be useful for the treatment or prophylaxis of other conditions in which the glycoprotein complex Gp Db/IIIa or other integrin receptors are implicated.
• the compounds of the invention may potentiate wound healing and be useful in the treatment of osteoporosis.
• the compounds of the invention may also be.useful for the treatment of certain cancerous diseases.
• compounds of the invention may be of use to prevent or delay metastasis in cancer.
• CO or a physiologically acceptable salt or solvate thereof for use in human or veterinary medicine, particularly for use in the treatment or prophylaxis of thrombotic disorders. .
• a compound of formula (T) or a physiologically acceptable salt or solvate thereof for the manufacture of a therapeutic agent for the treatment or prophylaxis of thrombotic disorders.
• a method of treating a human or animal subject suffering from or susceptible to a thrombotic disorder comprises administering to said subject an effective amount of a compound of formula (T) or a physiologically acceptable salt or solvate thereof.
• a compound of formula (T) may advantageously be used in conjunction with one or more other therapeutic agents.
• suitable agents for adjunctive therapy include thrombolytic agents or any other compound stimulating thrombolysis or fibrinolysis and cytotoxic drugs. It is to be understood that the present invention covers the use of a compound of formula (I) or a physiologically acceptable salt or solvate thereof in combination with one or more other therapeutic agents.
• compositions comprising a compound of formula (I) or a physiologically acceptable salt or solvate thereof adapted for use in human or veterinary medicine.
• Such compositions may conveniently be presented for use in conventional manner in admixture with one or more physiologically acceptable carriers or excipients.
• the compounds according to the invention may be formulated for administration in any suitable manner.
• the compounds may, for example, be formulated for topical administration or administration by inhalation or, more preferably, for oral or parenteral administration.
• the pharmaceutical composition may take the form of, for example, tablets, capsules, powders, solutions, syrups or suspensions prepared by conventional means with acceptable excipients.
• the pharmaceutical composition may be given as an injection or a continuous infusion (e.g. intravenously, intravascularly or subcutaneously).
• compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
• formulatory agents such as suspending, stabilising and/or dispersing agents.
• For administration by injection these may take the form of a unit dose presentation or as a multidose presentation preferably with an added preservative.
• the active ingredient may be in powder form for reconstitution with a suitable vehicle.
• the compounds of the invention may also be formulated as a depot preparation.
• Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
• the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
• the compounds of the invention may also be used in combination with other therapeutic agents.
• the invention thus provides, in a further aspect, a combination comprising a compound of formula (T) or a physiologically acceptable salt or solvate thereof together with another therapeutic agent, in particular a thrombolytic agent.
• compositions comprising a combination as defined above together with a pharmaceutically acceptable carrier or exdpient comprise a further aspect of the invention.
• the individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
• a proposed daily dosage of a compound of formula (I) for the treatment of man is 0.01 mg/kg to 30 mg/kg, which may be conveniently administered in 1 to 4 doses.
• the precise dose employed will depend on the age and condition of the patient and on the route of administration.
• a daily dose of 0. Img kg to lOmg/kg may be suitable for systemic administration.
• X 1 , X 2 , Y 1 , Y 2 , R 1 , R 2 and R 3 are as defined in formula CO above unless otherwise stated;
• R p represents a protecting group and
• Hal represents a halogen, e.g.bromine.
• alkylation e.g. ethylation
• a source of ammonia e.g. ammonium acetate
• an alcoholic solvent e.g. methanol
• an elevated temperature e.g. reflux
• carboxylic add protecting group e.g. ammonium acetate
• an alcoholic solvent e.g. methanol
• the alkylation may conveniently be effected by employing an appropriate trialkyloxonium salt (e.g. triethyloxonium tetrafiuoroborate) in a suitable solvent (e.g. dichloromethane) at room temperature.
• the alkylation e.g. methylation
• an alkyl halide e.g.
• hydroxylamine or an acid addition salt thereof e.g. hydroxylarnine hydrochloride
• a suitable base such as an alkali or alkaline earth metal carbonate or bicarbonate (e.g. potassium carbonate) and in a solvent such as an alcohol (e.g. methanol), followed, where necessary, by removing any protecting groups present.
• the reaction with hydroxylamine or an add addition salt thereof may conveniently be effected at an elevated temperature (e.g. reflux).
• compounds of formula (0 in which R 1 represents a C M alkyl or 2,2,2-trifluoroethyl group may be prepared by treating
• compounds of formula (T) in which R 1 represents a C M alkyl or 2,2,2-trifluoroethyl group may be prepared by treating compounds of formula (TV)
• R 4 represents an alkyl group, for example a C M alkyl group such as ethyl
• R 1 represents C M alkyl or 2,2,2-trifluoroethyl
• the reaction with the amine 'NI ⁇ may conveniently be carried out in a suitable solvent such as an alcohol (e.g. methanol) or an ether (e.g. tetrahydrofuran) at about room temperature.
• a suitable solvent such as an alcohol (e.g. methanol) or an ether (e.g. tetrahydrofuran) at about room temperature.
• Another process (D) for preparing compounds of formula (0 comprises deprotecting protected derivatives of compounds of formula (I).
• compounds of formula ( may be prepared from protected carboxyl derivatives of compounds of formula (T).
• Suitable carboxyl protection groups include, for example, those described in ⁇ Protective Groups in Organic Synthesis' by Theodora W. Green , second edition, (John Wiley and Sons, 1991) which also describes methods for the removal of such groups.
• Particular carboxyl protecting groups include, for example, carboxylic add ester groups such as carboxylic acid alkyl or aralkyl esters, for example where the alkyl or aralkyl portion of the ester function is methyl, ethyl, tert-butyl, methoxymethyl, benzyl, diphenyhnethyl, triphenylmethyl or p-nitrobenzyL When the ester is an unbranched alkyl (e.g.
• methyl) ester deprotection may be effected under conditions of acid hydrolysis, for . example using hydrochloric acid.
• Tert-butyl and triphenylmethyl ester groups may be removed under conditions of moderate add hydrolysis, for example using formic or trifluoroacetic add at room temperature or using hydrochloric add in acetic add.
• Benzyl, diphenyhnethyl and nitrobenzyl ester groups may be removed by hydrogenolysis in the presence of a metal catalyst (e.g. palladium).
• compounds of formula (I) may be prepared by interconversion, utilising other compounds of formula (I) as precursors.
• compounds of formula (I) in which R 1 represents a hydrogen atom may be prepared from corresponding compounds of formula (I) in which R 1 represents a hydroxyl group by catalytic hydrogenation in a solvent such as an alcohol e.g. ethanol.
• Suitable catalysts include Raney Nickel or conventional palladium or platinum catalysts.
• the required isomer may conveniently be separated using preparative high performance liquid chromatography (h.p.l.c.) applied to the final products of process (A)-(E) above or applied prior to any final deprotection step in said processes.
• preparative high performance liquid chromatography h.p.l.c.
• Compounds of formula (HI) may also be prepared from compounds of formula (V) by removing the carboxylic acid protecting group R p according to the method described in process (D) hereinabove.
• Compounds of formula (TV) may also be prepared from compounds of formula (V) by treating said compounds of formula (V) with an alcohol R 4 OH (where R 4 is as defined previously) under addic conditions, for example in the presence of an inorganic acid such as hydrochloric acid.
• R 4 is as defined previously
• compounds of formulae (VI) and (VU) may be heated (e.g. at reflux) in an aromatic hydrocarbon solvent (e.g. toluene), preferably containing molecular sieves, and in the presence of an add such as an alkane- or arylsulphonic acid (e.g. p-toluenesulphonic add), and the product thereof hydrogenated in an alcoholic solvent (e.g. ethanol) in the presence of a suitable transition metal catalyst such as palladium (e.g. palladium-on- carbon) at about room temperature.
• compounds of formulae (VI) and (VU) in the presence of an add such as hydrochloric acid and in a solvent such as an alcohol (e.g. methanol) may be treated with a reducing agent such as a borohydride reducing agent (e.g. sodium cyanoborohydride) and preferably also with molecular sieves.
• an aromatic hydrocarbon solvent e.g. toluene
• an add
• Compounds of formula (VU) may be prepared from a derivative of cyclohexane-l,4-dione in which one of the two oxo functions is protected (e.g. as a cyclic ketal) by treating said derivative with an anion of an acetic acid derivative CH 3 CO-R p followed by removal of the oxo protecting group.
• the anion may be generated using an alkyllithium reagent (e.g. n-butyllithium) in an inert solvent such as a hydrocarbon (e.g. n-hexane) or an ether (e.g.
• a cyclic ketal may be removed by treatment with a palladium reagent such as bis(acetonitrile)palladium (II) chloride in a solvent such as a ketone (e.g. acetone) at about room temperature or using an acid such as aqueous hydrochloric acid or a mixture of aqueous hydrochloric acid and acetic acid.
• a palladium reagent such as bis(acetonitrile)palladium (II) chloride in a solvent such as a ketone (e.g. acetone) at about room temperature or using an acid such as aqueous hydrochloric acid or a mixture of aqueous hydrochloric acid and acetic acid.
• a base such as an alkali or alkaline earth metal carbonate or bicarbonate (e.g. sodium bicarbonate) and in a suitable solvent such as an aprotic polar solvent (e.g. dimethylformamide, acetonitrile or dimethylsulphoxide), conveniently at an elevated temperature.
• a base such as an alkali or alkaline earth metal carbonate or bicarbonate (e.g. sodium bicarbonate)
• a suitable solvent such as an aprotic polar solvent (e.g. dimethylformamide, acetonitrile or dimethylsulphoxide), conveniently at an elevated temperature.
• aprotic polar solvent e.g. dimethylformamide, acetonitrile or dimethylsulphoxide
• Compounds of formula (TX) may be prepared from compounds of formula (VU) by reacting said compounds with a pipera ⁇ ne derivative or a protected (e.g. N-benzyl protected) piperazine derivative under reducing conditions, for example as described above for the reaction between compounds of formulae (VI) and (VTI), followed, where appropriate, by the removal of any N-protecting group present using conventional conditions.
• a pipera ⁇ ne derivative or a protected piperazine derivative under reducing conditions, for example as described above for the reaction between compounds of formulae (VI) and (VTI), followed, where appropriate, by the removal of any N-protecting group present using conventional conditions.
• Compounds of formula (XL) may be prepared by reacting compounds of formula (VHI) with a compound of formula (XII)
• the compound of formula (XII) may be prepared by hydrogenating a compound of formula (XLH)
• the hydrogenation may conveniently be effected in the presence of a suitable transition metal catalyst such as rhodium, preferably also with alumina, in a solvent such as an alcohol, e.g. ethanol, and preferably at an elevated pressure.
• a suitable transition metal catalyst such as rhodium, preferably also with alumina
• a solvent such as an alcohol, e.g. ethanol
• the compound of formula (XHT) is a known compound described by C. Alvarez el al in Synth. Commun. 1991, 21, 619.
• Suitable bases include alkali or alkaline earth metal carbonates such as sodium carbonate or potassium carbonate.
• the reaction may conveniently be effected in a solvent such as dimethylformamide or dimethylsulphoxide at an elevated temperature (e.g. 100°-200°C).
• a solvent such as dimethylformamide or dimethylsulphoxide at an elevated temperature (e.g. 100°-200°C).
• compounds of formula (XTV) are treated with benzyl bromide in an alcoholic solvent (e.g. ethanol) at an elevated temperature to provide a salt of formula (XV)
• Removal of the benzyl group and double bond from a compound of formula (XVI) provides the desired compounds of formula (VI).
• the removal of the benzyl group may conveniently be effected by hydrogenolysis in the presence of a palladium catalyst such as Pd(OH) 2 -on-carbon, or by reaction with 1-chloroethyl chlorofo ⁇ nate in the presence of a base such as "proton sponge' followed by treatment with methanol.
• the removal of the double bond may conveniently be effected by hydrogenation in the presence of a platinum catalyst such as platinum-on-carbon or platinum oxide and an acid (e.g. hydrochloric acid).
• Compounds of formula (XTV) may be prepared by converting compounds of formula (VDT) to the corresponding boronic acids of formula (XVLI)
• a 4-halopyridine such as 4- bromopyridine
• a suitable transition metal catalyst such as a palladium catalyst [e.g. tetrakis(triphenylphosphine)palladium(0)] and a suitable base such as an alkali metal carbonate (e.g. sodium carbonate).
• a suitable transition metal catalyst such as a palladium catalyst [e.g. tetrakis(triphenylphosphine)palladium(0)]
• a suitable base such as an alkali metal carbonate (e.g. sodium carbonate).
• the reaction may conveniently be effected in a solvent such as an aqueous ether (e.g. aqueous 1,2-ethanediol dimethyl ether).
• the compound of formula (XVUI) may be prepared from 4- bromopyridine by treating said compound with an alkyllithium reagent (e.g. n-butyllitbium) at a low temperature (e.g. about -78°C) in tetrahydrofuran, followed by reaction with a suitable boron reagent such as tr ⁇ sopropyl borate in the presence of an acid (e.g. hydrochloric add).
• an alkyllithium reagent e.g. n-butyllitbium
• a suitable boron reagent such as tr ⁇ sopropyl borate in the presence of an acid (e.g. hydrochloric add).
• Compounds of formula (VET) are either known compounds or may be prepared from the known compounds of formula (VET) using conventional chemistry.
• phenylation may be effected using a reagent PhB(OH) 2 in the presence of a palladium catalyst such as tetrakis(triphenylphosphine)palladium (0).
• Alkylation may also be effected using a tin reagent (R ⁇ Sn (where R 2 is C w alkyl) in the presence of a palladium catalyst such as bis (triphenylphosphine)benzylpalladium chloride.
• the desired stereochemistry of the product may be obtained either by commencing with an optically pure starting material or by resolving the racemic mixture at any convenient stage in the synthesis.
• Resolution of the final product, an intermediate or a starting material may be effected by any suitable method known in the art: see for example * Stereochemistry of Carbon Compounds' by E L Eliel (McGra Hill, 1962) and 'Tables of Resolving Agents' by S HWilen.
• Solvates (e.g. hydrates) of a compound of formula (I) may be formed during the work-up procedure of one of the aforementioned process steps.
• the following Preparations and Examples illustrate the invention but do not limit the invention in any way. All temperatures are in °C.
• System (A) is dichloromethane-ethanol-0.880 ammonia.
• Preparative high performance liquid chromatography (h.p.l.c.) was carried out using a Dynamax 60A C18 8 ⁇ M 25cm x 41.4mm i.d. column eluted with a mixture of solvents (A) 0.1% trifluoroacetic add in water and OB) 0.05% trifluoroacetic acid in acetonitrile.
• Analytical h.p.l.c. was carried out using a Dynamax 60A C18 8 ⁇ M 25cm x 4.6mm i.d. column using eluants as for preparative h.p.l.c.
• N.m.r. ( ⁇ , D 6 -DMSO) : 1.43 (9H,s,*Bu), 1.54, 1.76-2.02, 2.08, 3.58 (14H,m, cyclohexane and piperidine), 2.34 (2H,s,CH 2 CO 2 , Bu), 3.01 (lH,tt,piperidine CH), 3.06-3.26 (3H,m, cyclohexane CH and piperidine), 7.5, 7.82 (4H,AA ⁇ B', aromatics), 8.96-9,34 (5H,3xm, amidine and piperidine NIT).
• N.m.r. ( ⁇ , D 6 -DMSO) : 1.57, 1.75-2.05, 2.09 (12H,m, cyclohexane and piperidine), 2.37 (2H,s,CJH 4 CO 2 H), 3.01 (lH,tt, piperidine CH), 3.07- 3.28 (3H,m, cyclohexane CH and piperidine), 3.58 (2H,ddd, piperidine), 4.62 (lH,br.s,OH), 7.5, 7.81 (2H.AA ⁇ B' aromatics), 8.96-9.34 (5H,3xbrm, amidine and piperidine NIT).
• Example 7 Biological Data Inhibition of blood platelet aggregation by compounds of the invention was determined according to the following procedure. Citrated whole blood (1 part 3.8% trisodium citrate : 9 parts blood) was obtained from human volunteers, free of medication for at least 10 days prior to collection. The blood was incubated with O.lmM aspirin and 0.05 ⁇ M prostacyclin and then centrifuged at lOOOg for 4 minutes (20°C). The supernatant platelet rich plasma (PRP) was further centrifuged at 1300g for 10 minutes
• microcrystalline cellulose, lactose and cross-linked polyvinylpyrrolidone are sieved through a 500 micron sieve and blended in a suitable mixer.
• the magnesium stearate is sieved through a 250 micron sieve and blended with the active blend.
• the blend is compressed into tablets using suitable punches.
• the compound of the invention, lactose and pregelatinised starch are blended together and granulated with water.
• the wet mass is dried and milled.
• the magnesium stearate and cross-linked polyvinylpyrrolidone are screened through a 250 micron sieve and blended with the granule.
• the resultant blend is compressed using suitable tablet punches.
• the compound of the invention and pregelatinised starch are screened through a 500 micron mesh sieve, blended together and lubricated with magnesium stearate, (meshed through a 250 micron sieve).
• the blend is filled into hard gelatine capsules of a suitable size.
• the compound of the invention and lactose are blended together and granulated with a solution of polyvinylpyrrolidone.
• the wet mass is dried and milled.
• the magnesium stearate and cross-linked polyvinylpyrrolidone are screened through a 250 micron sieve and blended with the granules.
• the resultant blend is filled into hard gelatine capsules of a suitable size.
• the hydroxypropyl methylcellulose is dispersed in a portion of hot purified water together with the hydroxybenzoates and the solution is allowed to cool to room temperature.
• the saccharin sodium flavours and sorbitol solution are added to the bulk solution.
• the compound of the invention is dissolved in a portion of the remaining water and added to the bulk solution. Suitable buffers may be added to control the pH in the region of maximum stability.
• the solution is made up to volume, filtered and filled into suitable containers.
• Sodium chloride may be added to adjust the tonicity of the solution and the pH may be adjusted to that of maximum stability and/or to facilitate solution of the compound of the invention using dilute add or alkali or by the addition of suitable buffer salts.
• Antioxidants and metal chelating salts may also be included.
• the solution is prepared, clarified and filled into appropriate sized ampoules sealed by fusion of the glass.
• the injection is sterilised by heating in an autoclave using one of the acceptable cycles.
• the solution may be sterilised by filtration and filled into sterile ampoules under aseptic conditions.
• the solution may be packed under an inert atmosphere of nitrogen.

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Diabetes (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Hematology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Hydrogenated Pyridines (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=10703062

Family Applications (2)

Family Applications After (1)

Country Status (10)

Families Citing this family (20)

Family Cites Families (2)

• 1991
  • 1991-10-16 GB GB919122016A patent/GB9122016D0/en active Pending
• 1992
  • 1992-10-12 WO PCT/EP1992/002340 patent/WO1993008181A1/en not_active Application Discontinuation
  • 1992-10-12 JP JP5507408A patent/JPH07500327A/ja active Pending
  • 1992-10-12 AU AU26892/92A patent/AU2689292A/en not_active Abandoned
  • 1992-10-12 EP EP92921322A patent/EP0609282A1/de not_active Withdrawn
  • 1992-10-13 TW TW081108133A patent/TW217409B/zh active
  • 1992-10-13 EP EP92309308A patent/EP0537980A1/de not_active Withdrawn
  • 1992-10-15 IL IL103437A patent/IL103437A0/xx unknown
  • 1992-10-15 MX MX9205916A patent/MX9205916A/es unknown
  • 1992-10-15 ZA ZA927955A patent/ZA927955B/xx unknown
  • 1992-10-15 CN CN92113088A patent/CN1073433A/zh active Pending

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events